DiscoverPharma and BioTech Daily
Pharma and BioTech Daily
Claim Ownership

Pharma and BioTech Daily

Author: Pharma and BioTech News

Subscribed: 141Played: 2,634
Share

Description

Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.

Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.

Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai

375 Episodes
Reverse
Blackstone commits up to 1.5 billion dollars to Pfizer's monthly obesity shot berobenatide, and Reuters reports the FDA has shelved its Commissioner's National Priority Voucher program. Also: FDA staffing gaps, a Bristol Myers Squibb R&D overhaul, Windward Bio's 175 million dollar IPO and a 105 million dollar Series B for Neurosterix. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Friday, November 13. Today, private equity puts up se...
The FDA adds a possible NAION vision loss risk to the labels of all GLP-1 drugs, and Compass Pathways completes its psilocybin application for treatment resistant depression. Plus AstraZeneca buys Omniose, Abeona licenses a Phase three ready esophagitis drug, Valo and Montai merge, and Zura Bio drops a Phase two program. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Thursday, November 12. Today, the FDA adds a vision warning to every GL...
Beam Therapeutics' base editing therapy risto-cel meets its primary endpoint in the pivotal BEACON sickle cell study, and the FDA approves Pimjetmi, pimicotinib, from Abbisko and Merck KGaA for tenosynovial giant cell tumor. Also: BIO's BioAdvance plan to keep the US ahead of China in biotech, Gossamer Bio prepares a seralutinib launch after its first NDA, and the FDA clears Metagenomi's MGX-001 gene insertion trial in hemophilia A. Good morning from Pharma and Biotech Daily, the briefing on...
Vir Biotechnology reports a pivotal Phase 3 win in chronic hepatitis delta, and argenx agrees to buy Unnatural Products for up to 1.15 billion dollars to add oral macrocyclic peptides. Also: TG Therapeutics raises Briumvi guidance, Xenon's azetukalner filing and X-NOVA2 timing, and Atea's path to a hepatitis C filing. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Tuesday, November 10. Vir Biotechnology has a pivotal win in hepatitis del...
Full Lp(a)HORIZON results at AHA show Novartis' pelacarsen cut Lp(a) by 78 percent with no cardiovascular benefit, as the FDA heads into a crowded month of decisions on ivonescimab, deramiocel and povetacicept. Also: Mineralys' lorundrostat holds its effect at 48 weeks, Sarepta's new CEO faces falling Elevidys sales, and Moderna raises guidance. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Monday, November 9. Since Friday, a large outc...
loading
Comments